HemaCare Announces Expansion of Disease State Cells for Bioresearch
HemaCare expands disease state portfolio of primary human blood for cell therapy research and developement
(Los Angeles, CA – July 17, 2017) HemaCare Corporation (OTCBB: HEMA), a leading provider of human blood and immune cells for bioresearch announced today that it has expanded its portfolio of disease state materials in response to increased demand from therapeutic and diagnostic developers. Recent additions to the portfolio include serum from rare diseases such as Granulomatosis with Polyangiitis (GPA), and Mixed Connective Tissue Disease (MCTD), Dermatomyositis and Polymyositis (PM/DM), as well as plasma or serum from infectious diseases including HIV, Hepatitis, Zika, and Dengue Fever. HemaCare continues to expand its biorepository of cryopreserved peripheral blood mononuclear cells (PBMCs), popularly used for drug discovery and development projects. The disease state cells in greatest demand include various leukemias and lymphomas (including AML and CLL), multiple myeloma, solid tumors (including breast and lung cancer), and common autoimmune diseases (including Multiple Sclerosis, Lupus, and Rheumatoid Arthritis). Researchers utilize immune cells or plasma and serum from patients with a diagnosed disease for pre-clinical research and testing for new therapies, including drug target discovery and effectiveness in the patient population. In addition to freshly collected blood products, HemaCare offers “matched sets” of cryopreserved PBMCs and plasma and/or serum from a variety of in-stock disease state samples.
“We continue to respond to market demand for high quality blood cells to address increasingly diverse applications of cell therapy and diagnostics,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We have secured our access to cells from donors with various disease states through partnerships with specialty physicians and clinics across the country. These partnerships will expand our customer base as well as serve new initiatives for our existing customers in cell therapy and bio-pharmaceutical companies.”
HemaCare Corporation is a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy. Our expertise has evolved through 39 years in the business of blood collection, processing and storage. In addition, we have established a robust donor recruitment and management system which supports an extensive registry of well-characterized repeat donors. HemaCare’s controlled procedures ensure a readily available inventory of high-quality, consistent and selectable primary human cells and biological products for advanced biomedical research. Our customers are engaged in basic research and development of clinical therapies that are designed to manipulate the immune system for treatment and cure of cancer, degenerative diseases and immune and genetic disorders. HemaCare’s products and services address several key markets, including immune therapy research, cell manufacturing for clinical therapy, and clinical laboratory instrument development. We specialize in custom cell collections for customers who may require donors with specific attributes (phenotypic or disease state, for example), or sub-sets of immune cells that can be selected in our laboratory using the latest technology. HemaCare’s products and services address all stages of cell therapy development, from basic biological research in academic institutions to pharmaceutical cell development in large drug companies. For more information, please visit www.hemacare.com.